Eli Lilly Aktie
804,00USD | -22,25USD | -2,69% |
WKN: 858560 / ISIN: US5324571083
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 89,61 |
Lilly Endowment, Inc. | 10,21 |
Lilly Endowment, Inc. | 10,21 |
The Vanguard Group, Inc. | 7,54 |
Vanguard Group, Inc. (Subfiler) | 7,39 |
PNC Financial Services Group, Inc. (13F Subfiler) | 5,41 |
PNC Bank, NA (Investment Management) | 5,39 |
State Street Corp. | 3,57 |
Vanguard Total Stock Market ETF | 2,84 |
Fidelity Management & Research Co. LLC | 2,53 |
BlackRock Fund Advisors | 2,46 |
Vanguard 500 Index Fund | 2,20 |
Capital Research & Management Co. (World Investors) | 2,14 |
T Rowe Price Associates, Inc. (13F Subfiler) | 2,09 |
BlackRock Institutional Trust Co. NA | 1,87 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 33 625 | 35 000 | 35 000 | 39 000 | 43 000 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,66 | 0,70 | 0,81 | 0,73 | 0,79 |
Bilanz (in Mio. USD) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 13 710 | 17 462 | 18 452 | 18 035 | 25 727 |
Summe Anlagevermögen | 25 577 | 29 171 | 30 354 | 31 455 | 38 279 |
Summe Aktiva | 39 286 | 46 633 | 48 806 | 49 490 | 64 006 |
Bilanz (in Mio. USD) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 36 587 | 40 808 | 39 651 | 38 714 | 53 143 |
Summe Eigenkapital | 2 699 | 5 825 | 9 155 | 10 775 | 10 864 |
Summe Passiva | 39 286 | 46 633 | 48 806 | 49 490 | 64 006 |
Adresse
Lilly Corporate Center, 46285 Indianapolis | |
Telefon | +1 (317) 276-2000 |
Internet | http://www.lilly.com |
Management
Alonzo Weems
Executive VP, Chief Ethics & Compliance Officer |
Anat Hakim
Secretary, Executive VP & General Counsel |
Andy Vicari
Senior Director & US Brand Leader-Insulins |
Anne E. White
Executive Vice President-Lilly Neuroscience |
Christian Nguyen
VP-Global Patient Outcomes & Real World Evidence |
Daniel M. Skovronsky
Chief Scientific Officer & Executive VP |
David A. Ricks
Chairman, President & Chief Executive Officer |
David Hyman
Chief Medical Officer |
Diogo Rau
Executive VP, Chief Information & Digital Officer |
Donald A. Zakrowski
Chief Accounting Officer & Vice President-Finance |
Edgardo Hernandez
President-Manufacturing Operations & Senior VP |
Eric Dozier
Executive VP-Human Resources & Diversity |
Gabrielle G. Greene-Sulzberger
Independent Director |
Ilya Yuffa
Senior VP & President-Lilly Bio Medicines |
Jacob S. van Naarden
Executive Vice President |
Jamere Jackson
Independent Director |
Jennifer Oleksiw
Global Chief Customer Officer & Vice President |
Joe Fletcher
Investor Relations Contact |
Jon Erik Fyrwald
Independent Director |
Jon R. Moeller
Director |
Juan Ricardo Luciano
Lead Independent Director |
Katherine Baicker
Independent Director |
Kim Macko
Head-Global Brand Development |
Kimberly H. Johnson
Independent Director |
Laura A. Lane
Vice President |
Lucas E. Montarce
Chief Financial Officer & Executive Vice President |
Mark Genovese
Senior Vice President-Immunology Development |
Mary Lynne Hedley
Independent Director |
Melissa Seymour
Executive Vice President-Global Quality |
Nathaniel R. Miles
Vice President-Strategic Initiatives |
Patrik Jonsson
EVP, President-Lilly Diabetes & Obesity |
Ralph Alvarez
Independent Director |
Robert Conley
Development Leader-Neuroscience |
Robert J. Heine
Vice President-Medical Affairs |
Ruth Gimeno
Vice President |
Thomas Fuchs
Chief Artificial Intelligence Officer |
Travis Coy
VP, Head-Transactions & Business Development |
William G. Kaelin
Independent Director |